Tocagen appoints John Wood as Vice President, Regulatory Affairs and Quality Assurance

Wood holds more than 20 years of regulatory affairs experience focusing on drugs for diseases with high unmet need

Tocagen, a California-based clinical stage, cancer-selective gene therapy company, has named John Wood as Vice President of Regulatory Affairs and Quality Assurance.

Wood holds more than 20 years of regulatory affairs experience focusing on drugs for diseases with high unmet need. While at IDEC Pharmaceuticals he played a leading role, in collaboration with Genentech, in the first regulatory approval of Rituxan for the treatment of immune system B-cell malignancies.

Prior to joining Tocagen, Wood led regulatory affairs at Arena Pharmaceuticals. Before this he led regulatory affairs and alliance management at Amylin Pharmaceuticals.

Wood has also held regulatory leadership positions at Quintiles Consulting and Gensia.

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now